The cytoplasmic domains of CD28H and of the ζ chain were both required for this activity, indicating that CD28H is a powerful activation receptor of NK cells that broadens their antitumor activity and holds promise as a component of NK-based CARs for cancer immunotherapy [169]. Here, TMIGD2 is linked to cancer.